Articles related to HEALTHCARE ACCESS

US cancer centers are enrolling fewer patients in clinical trials despite continued global therapeutic advances, raising concerns about access, competitiveness, and whether trials are fully integrated into standard oncology care.

The FDA has begun reviewing generic tirzepatide applications as global competition accelerates, despite US patent protections limiting near-term availability.

ASHP urged HRSA in a June 2 letter to take immediate enforcement action against Eli Lilly after the manufacturer gave an initial group of 340B-covered entities five business days to submit detailed claims-level data or lose access to discounted pricing across its full drug portfolio, including in-house hospital pharmacy dispensing and medically administered products; as of mid-June, the threatened cutoffs had not yet taken effect for many affected entities.

The Main Street Pharmacy Access Act (H.R. 3164/S. 2426), which would authorize Medicare reimbursement for pharmacist-provided testing and treatment of flu, strep, RSV, and COVID-19 in states that already permit those services, cleared the House Committee on Ways and Means on May 21 with more than 110 congressional co-sponsors and support from over 170 organizations.

A digital patient navigation platform exceeded standard web-based engagement benchmarks in connecting melanoma patients with subspecialty oncology care across an academic center and regional health system network, though transition to multidisciplinary care remained more common at the academic site.

Nearly 18 million US women aged 45–64 were overdue for at least one recommended breast, cervical, or colorectal cancer screening, with colorectal cancer representing the largest unmet need in a 2024 BRFSS analysis of 36.2 million women.